Fresenius Kabi vedolizumab biosimilar PB016 accepted for FDA, EMA review
Fresenius names Thomas Thestrup head of new Ventures unit
Fresenius establishes venture fund of more than €200 million to drive healthcare innovation | FSNUY Stock News
Deutsche Bank Reaffirms Their Buy Rating on Fresenius SE & Co. KGaA (0OO9)
Fresenius to publish Q2 2026 financial results
Jefferies Keeps Their Buy Rating on Fresenius SE & Co. KGaA (0OO9)